Document is current
Any future updates will be listed below
-
Authors
Knikman, Jonathan E. http://orcid.org/0000-0002-6798-7247
Zhai, Qinglian
Lunenburg, Carin A. T. C.
Henricks, Linda M.
Böhringer, Stefan
van der Lee, Maaike
de Man, Femke M.
Offer, Steven M.
Shrestha, Shikshya
Creemers, Geert-Jan
Baars, Arnold
Dezentjé, Vincent O.
Imholz, Alexander L. T.
Jeurissen, Frank J. F.
Portielje, Johanna E. A.
Jansen, Rob L. H.
Hamberg, Paul
Droogendijk, Helga J.
Koopman, Miriam
Nieboer, Peter
van de Poel, Marlène H. W.
Mandigers, Caroline M. P. W.
van Schaik, Ron H. N.
Gelderblom, Hans
Mathijssen, Ron H. J.
Schellens, Jan H. M.
Cats, Annemieke
Guchelaar, Henk-Jan
Swen, Jesse J.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (NKI2013-6249)
ZonMw (848016007)
- License Information
-
More Information
Article History
Received: 29 March 2024
Accepted: 6 June 2024
First Online: 15 August 2024
Declarations
:
: This study was approved by the institutional review board of the Netherlands Cancer Institute (Amsterdam, The Netherlands) and approval from the board of directors of each individual hospital was obtained for all participating centers and conformed to the principles of the Helsinki Declaration. No additional informed consent was needed as patients from the Alpe-DPD study which was approved by the institutional review board of The Netherlands Cancer Institute (Amsterdam, Netherlands) had already consented to use of their data for future studies, and data from the patients from routine clinical care were anonymized.
: Not applicable.
: The authors declare no conflict of interest in relationship with this work. Carin Lunenburg is currently employed by Bristol-Myers Squibb, not related to the contents of this manuscript. She was supported by an unrestricted grant from Roche Pharmaceuticals. Jan Schellens is an (part time) employee, stock- and patent holder of Modra Pharmaceuticals, a spin out company developing oral taxane formulations; Jan Schellens is also a part time employee of Byondis bv and received consultancy fees from Debiopharm, all not related to the contents of the manuscript. Steven Offer has received consultancy fees from Processa Pharmaceuticals, Inc. for activities not related to the contents of this manuscript. The remaining authors declare that they have no competing interests.
